No such discussions have taken place recently.

The clinical and cost-effectiveness of testing for Group B Streptococcus: a cluster randomised trial with economic and acceptability evaluations (GBS3) trial is currently still recruiting participants. We expect these findings, as with all research funded via the National Institute for Health and Care Research, to be published following a full analysis of the trial data.

Midwives are a key source of information for new and expectant parents on Group B Strep (GBS), so it is critical that they are well-informed, and this awareness will help eliminate these serious, yet often avoidable, infections in new-born babies.

NHS England published a revised Core Competency Framework in May 2023; it covers the mandated training for all maternity services which now includes GBS. Undertaking this training will increase awareness and understanding of GBS, enabling midwives and doctors to be better informed when speaking to families about the risk of GBS in labour. The Core Competency Framework is incentivised through the maternity incentive scheme administrated by NHS Resolution.

The Royal College of Midwives (RCM) has an evidence-based i-learn module on GBS that is freely available to RCM members. It would be beneficial for as many midwives as possible to take the training to increase awareness of GBS.

Screening for GBS is not routinely offered to all pregnant women in the United Kingdom. However, if it is detected during pregnancy through routine testing, it will be managed in accordance with Trust protocol and information leaflets will be provided on treatment and any associated risks. GBS testing is usually only offered to women who have had GBS in a previous pregnancy, in which case, testing will be carried out by the Trust providing care.

The Office for Health Improvement and Disparities and NHS England continue to work with system partners across England on the Group B Strep trial, which is currently underway as a multi-centre randomised controlled trial with 71 hospital sites included. It is looking at whether routine testing of women for GBS, either in late pregnancy or during labour, reduces the occurrence of early-onset neonatal sepsis, compared to the current risk factor-based strategy.

Midwives are a key source of information for new and expectant parents on Group B Strep (GBS), so it is critical that they are well-informed, and this awareness will help eliminate these serious, yet often avoidable, infections in new-born babies.

NHS England published a revised Core Competency Framework in May 2023; it covers the mandated training for all maternity services which now includes GBS. Undertaking this training will increase awareness and understanding of GBS, enabling midwives and doctors to be better informed when speaking to families about the risk of GBS in labour. The Core Competency Framework is incentivised through the maternity incentive scheme administrated by NHS Resolution.

The Royal College of Midwives (RCM) has an evidence-based i-learn module on GBS that is freely available to RCM members. It would be beneficial for as many midwives as possible to take the training to increase awareness of GBS.

Screening for GBS is not routinely offered to all pregnant women in the United Kingdom. However, if it is detected during pregnancy through routine testing, it will be managed in accordance with Trust protocol and information leaflets will be provided on treatment and any associated risks. GBS testing is usually only offered to women who have had GBS in a previous pregnancy, in which case, testing will be carried out by the Trust providing care.

The Office for Health Improvement and Disparities and NHS England continue to work with system partners across England on the Group B Strep trial, which is currently underway as a multi-centre randomised controlled trial with 71 hospital sites included. It is looking at whether routine testing of women for GBS, either in late pregnancy or during labour, reduces the occurrence of early-onset neonatal sepsis, compared to the current risk factor-based strategy.

Midwives are a key source of information for new and expectant parents on Group B Strep (GBS), so it is critical that they are well-informed, and this awareness will help eliminate these serious, yet often avoidable, infections in new-born babies.

NHS England published a revised Core Competency Framework in May 2023; it covers the mandated training for all maternity services which now includes GBS. Undertaking this training will increase awareness and understanding of GBS, enabling midwives and doctors to be better informed when speaking to families about the risk of GBS in labour. The Core Competency Framework is incentivised through the maternity incentive scheme administrated by NHS Resolution.

The Royal College of Midwives (RCM) has an evidence-based i-learn module on GBS that is freely available to RCM members. It would be beneficial for as many midwives as possible to take the training to increase awareness of GBS.

Screening for GBS is not routinely offered to all pregnant women in the United Kingdom. However, if it is detected during pregnancy through routine testing, it will be managed in accordance with Trust protocol and information leaflets will be provided on treatment and any associated risks. GBS testing is usually only offered to women who have had GBS in a previous pregnancy, in which case, testing will be carried out by the Trust providing care.

The Office for Health Improvement and Disparities and NHS England continue to work with system partners across England on the Group B Strep trial, which is currently underway as a multi-centre randomised controlled trial with 71 hospital sites included. It is looking at whether routine testing of women for GBS, either in late pregnancy or during labour, reduces the occurrence of early-onset neonatal sepsis, compared to the current risk factor-based strategy.

Midwives are a key source of information for new and expectant parents on Group B Strep (GBS), so it is critical that they are well-informed, and this awareness will help eliminate these serious, yet often avoidable, infections in new-born babies.

NHS England published a revised Core Competency Framework in May 2023; it covers the mandated training for all maternity services which now includes GBS. Undertaking this training will increase awareness and understanding of GBS, enabling midwives and doctors to be better informed when speaking to families about the risk of GBS in labour. The Core Competency Framework is incentivised through the maternity incentive scheme administrated by NHS Resolution.

The Royal College of Midwives (RCM) has an evidence-based i-learn module on GBS that is freely available to RCM members. It would be beneficial for as many midwives as possible to take the training to increase awareness of GBS.

Screening for GBS is not routinely offered to all pregnant women in the United Kingdom. However, if it is detected during pregnancy through routine testing, it will be managed in accordance with Trust protocol and information leaflets will be provided on treatment and any associated risks. GBS testing is usually only offered to women who have had GBS in a previous pregnancy, in which case, testing will be carried out by the Trust providing care.

The Office for Health Improvement and Disparities and NHS England continue to work with system partners across England on the Group B Strep trial, which is currently underway as a multi-centre randomised controlled trial with 71 hospital sites included. It is looking at whether routine testing of women for GBS, either in late pregnancy or during labour, reduces the occurrence of early-onset neonatal sepsis, compared to the current risk factor-based strategy.

Midwives are a key source of information for new and expectant parents on group B Strep (GBS), so it is critical that they are well-informed. Awareness of GBS helps eliminate this serious, yet often avoidable, infections in new-born babies. An evidence-based i-learn module on GBS is freely available to all Royal College of Midwives members and midwives are encouraged to undertake this training to increase their knowledge around GBS.

Additionally, the Government’s national Start4Life programme provides advice and practical guidance to parents-to-be and families with babies and under five years old, to help them adopt healthy behaviours and build parenting skills. The Start4Life website offers guidance for all pregnant mothers, including those from Black and Asian backgrounds, on GBS. The guidance is available at the following link:

https://www.nhs.uk/start4life

Midwives are a key source of information for new and expectant parents on group B strep (GBS), so it is critical that they are well-informed and this awareness will help eliminate these serious, yet often avoidable, infections in new-born babies. Group B Strep Support and the Royal College of Midwives (RCM) have an evidence-based i-learn module on GBS that is freely available to RCM members. It would be beneficial for as many midwives as possible to take the training to increase awareness of GBS.

Public Health England’s national programme Start4Life provides advice and practical guidance to parents-to-be and families with babies and under five years old, to help them adopt healthy behaviours and build parenting skills. The Start4Life website offers guidance for pregnant mothers on GBS which is available at the following link:

https://www.nhs.uk/start4life

Screening for GBS is not routinely offered to all pregnant women in the United Kingdom. A risk-based approach has been adopted, whereby those women identified as at risk of having a baby affected by GBS are offered antibiotics in labour.

The GBS carriage rate varies among racial groups, however the highest rates occur within people of black African ancestry and the lowest in people of South Asian ancestry. Evidence shows that continuity of carer can significantly improve outcomes for women and their babies from ethnic minorities and those living in deprived areas. NHS England wrote to all trusts regarding the Midwifery Continuity of Carer (MCoC) stating that where locally it is decided that provision of MCoC can continue, NHS England continues to encourage prioritised rollout to areas with a high proportion of Black, Asian and mixed ethnicity women, as well as areas of high deprivation.

Midwives are a key source of information for new and expectant parents on group B strep (GBS), so it is critical that they are well-informed and this awareness will help eliminate these serious, yet often avoidable, infections in new-born babies. Group B Strep Support and the Royal College of Midwives (RCM) have an evidence-based i-learn module on GBS that is freely available to RCM members. It would be beneficial for as many midwives as possible to take the training to increase awareness of GBS.

Public Health England’s national programme Start4Life provides advice and practical guidance to parents-to-be and families with babies and under five years old, to help them adopt healthy behaviours and build parenting skills. The Start4Life website offers guidance for pregnant mothers on GBS which is available at the following link:

https://www.nhs.uk/start4life

Screening for GBS is not routinely offered to all pregnant women in the United Kingdom. A risk-based approach has been adopted, whereby those women identified as at risk of having a baby affected by GBS are offered antibiotics in labour.

The GBS carriage rate varies among racial groups, however the highest rates occur within people of black African ancestry and the lowest in people of South Asian ancestry. Evidence shows that continuity of carer can significantly improve outcomes for women and their babies from ethnic minorities and those living in deprived areas. NHS England wrote to all trusts regarding the Midwifery Continuity of Carer (MCoC) stating that where locally it is decided that provision of MCoC can continue, NHS England continues to encourage prioritised rollout to areas with a high proportion of Black, Asian and mixed ethnicity women, as well as areas of high deprivation.

The Department has no plans to do so at present.

Should the evidence base develop further, clinical policy may be updated by relevant organisations such as the National Institute for Health and Care Excellence. NHS England would then consider the development of care pathways for those living with paediatric acute-onset neuropsychiatric syndrome and paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. In the meantime, integrated care systems are responsible for planning care for their populations.

Medical professionals, such as general practitioners, are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This activity should include taking account of new research and developments in guidance to ensure that they can continue to provide high quality care to all patients.

Supply issues affecting antibiotics used to treat Strep A appear to be improving, as decisive action has been taken to boost supply and demand has reduced. We are continuing to work with manufacturers and wholesalers to ensure that they expedite deliveries, bring forward stock they have to make sure it gets to where it is needed, and boost supply to meet demand.

We have issued eight Serious Shortage Protocols (SSPs) to allow pharmacists to supply an alternative form of penicillin V, or alternative antibiotic, to make things easier for them, patients, and GPs.

Supply issues affecting antibiotics used to treat Strep A appear to be improving, as decisive action has been taken to boost supply and demand has reduced. We are continuing to work with manufacturers and wholesalers to ensure that they expedite deliveries, bring forward stock they have to make sure it gets to where it is needed, and boost supply to meet demand.

We have issued eight Serious Shortage Protocols (SSPs) to allow pharmacists to supply an alternative form of penicillin V, or alternative antibiotic, to make things easier for them, patients, and GPs.

We have taken decisive action to boost supply of antibiotics used to treat Strep A and demand has reduced. We are continuing to work with manufacturers and wholesalers to ensure that they expedite deliveries, bring forward stock they have to make sure it gets to where it is needed and boost supply to meet demand. We have issued eight Serious Shortage Protocols to allow pharmacists to supply an alternative form of penicillin V, or alternative antibiotic, to make things easier for them, patients and general practices.

The continued demand for antibiotics to treat Strep A is making it difficult for some pharmacies to obtain certain antibiotics. We have been taking decisive action to address these temporary issues and to improve access to these medicines. These actions include working with manufacturers and wholesalers to expedite deliveries, bring forward existing stock to help ensure it gets to where it is needed and to boost supply to meet demand as quickly as possible. Deliveries to wholesalers and pharmacies are currently being made, with more expected in the coming days and week.

Eight Serious Shortage Protocols have been issued to allow pharmacists to supply an alternative form of penicillin V, or alternative antibiotic, if they do not have the specific product stated on the prescription.

We are taking decisive action to address temporary supply issues with some antibiotics that can be used to treat Strep A and to improve access to these medicines by continuing to work with manufacturers and wholesalers to expedite deliveries, bring forward stock they have to help ensure it gets to where it is needed and to boost supply to meet demand as quickly as possible.

Eight Serious Shortage Protocols have been issued for penicillin medicines, which will help mitigate local supply issues and allow pharmacists to supply alternative forms of the medicine, or alternative antibiotics, if they don’t have the specific product stated on the prescription.

The Department has well-established procedures to deal with medicine supply issues and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others within the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.

Rapid tests for Group A Streptococcus (Strep A) are not currently recommended by the National Institute for Health and Care Excellence (NICE) for individuals aged five years old and over presenting with a sore throat. However, in response to the ongoing national increased incidence of Strep A infection, UK Health Security Agency (UKHSA) are concurrently reviewing the literature on clinical scoring tools and rapid tests for Strep A infection in people presenting with a sore throat.

UKHSA have commissioned a desktop to bedside review of existing antigen-based lateral flow devices for Strep A infection, adopting a tried and tested process that was developed for coronavirus testing device approvals. This process will identify the tests that are most likely to perform well in the diagnosis of sore throats caused by Strep A in community settings.

No specific assessment of the extra costs to the National Health Service associated with commercial tests have been made.

We are continuing to work with manufacturers and wholesalers to accelerate deliveries to address temporary issues with the supply of antibiotics used to treat Group A Streptococcus and meet current demand.

We have introduced eight Serious Shortage Protocols in the United Kingdom for penicillin medicines to mitigate and support fulfilment times and local supply issues. This allows pharmacists to supply alternative forms of the medicine or alternative antibiotics, if the product stated on the prescription is unavailable. Data on fulfilment times for prescription only medicines is not held centrally.

The Essential Medicines Buffer Stock (EMBS) programme formally ended in 2019/2020. A small number of products were, however, retained in the EMBS to March 2022 as part of the COVID-19 Supportive Medicines stockpile. There are no plans to reinstate the EMBS.

We are taking decisive action to address temporary supply issues with some antibiotics that can be used to treat Strep A and to improve access to these medicines by continuing to work with manufacturers and wholesalers to speed up deliveries, bring forward stock they have to help ensure it gets to where it is needed and to boost supply to meet demand as quickly as possible.

Further, Serious Shortage Protocols have been issued across the United Kingdom for penicillin medicines, which will help mitigate local supply issues and allow pharmacists to supply alternative forms of the medicine, or alternative antibiotics, if they don’t have the specific product stated on the prescription.

The Department is working urgently with manufacturers and wholesalers to explore what can be done to expedite deliveries and bring forward stock they have to help ensure it gets to where it is needed, to meet demand as quickly as possible and support access to these vital medicines.

Further, Serious Shortage Protocols (SSPs) have been issued across the United Kingdom for penicillin medicines, which will help mitigate local supply issues by allowing pharmacists to supply alternative forms of the medicine, or alternative antibiotics, if they do not have the product stated on the prescription.

The UK Health Security Agency (UKHSA) has declared a national enhanced incident to co-ordinate the public health response. The UKHSA is working with schools and general practitioners to provide information on scarlet fever and Group A streptococcus, including relevant information for parents to understand the symptoms for urgent referrals for children with more serious cases. We are undertaking research to understand how parents are responding to this information.

A surveillance report and communications for the health system have been published to raise awareness among frontline clinicians. On 2 December, an alert was issued to remind clinicians of their legal duty to notify cases. Guidance has been issued to support clinical diagnosis, promote appropriate use of antimicrobials whilst ensuring patient safety.